Dual D 2 /5-HT 2 antagonist as an antipsychotic agent

Antineoplastic phospholipid, being effective against many tumor types, including ovary, non-small cell lung, kidney, and melanoma, exhibiting competitive inhibition of protein kinase C (PKC) activity

Novel allosteric inhibitor of IκBα phosphorylation and NF-κB transcriptional activity through selective capture of the inactive conformation and hence blockade of IKKβ S177/S181 phosphorylation

Natural Inhibitor of Clathrin-Mediated Endocytosis

Novel dual SMO-HDAC antagonist, retaining similar specificity for SAHA-targeted HDACs, disabling deviant Hedgehog signaling and preventing GLI binding to DNA

Highly potent fluorescent iGlu receptor antagonist

Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy

Novel Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy

First Small-Molecule Inhibitor of RNA-Binding Protein IGF2BP2/IMP2 for Cancer Therapy

Novel Type I Interferon Inducer; Intercalator of DNA; Inhibitor of the retrovirus replications including HIV

Novel Type I Interferon Inducer

Novel Type I Interferon Inducer

Selective serotonin 5-HT2A receptor antagonist

Angiotensin converting enzyme (ACE) inhibitor

Novel immunomodulatory and antibiofilm innate defense regulator peptide

Innate Defence Regulator Peptide, Enhancing Monocyte Migration and Adhesion on Fibronectin

Novel concentration dependent bactericidal agent against M. tuberculosis, being markedly more efficient at killing M. tuberculosis under acidic conditions

Novel bactericidal agent against M. tuberculosis under acidic conditions, being effective at sterilizing cultures in a concentration-dependent fashion at the highest concentrations

Selective ER modulator (SERM)

The first inhibitor targeting both IDO1/2 that has excellent in vitro inhibitory activity (IDO1 IC50 = 28 nM and IDO2 IC50 = 144 nM)

Novel mutant-selective Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitor

Novel isocitrate dehydrogenase 2 (IDH2) mutants inhibitor for the treatment of cancer

Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations

Novel highly potent substrate-selective inhibitor of insulin-degrading enzyme (IDE), blocking insulin binding while allowing glucagon cleavage, even at saturating inhibitor concentrations

M1 and M2 Antagonist

Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist

Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist

Novel μ,δ-Opioid Receptor Dual-Biased Agonist, Overcoming the Limitation of Prior Biased Agonist

Potent cytotoxin selectively by CYP1A1 as a tumor-selective treatment for human bladder cancers

DNA topoisomerase II inhibitor